Baird served as bookrunner on this offering
AboutCellular Biomedicines Group Inc. (“CBMG” or the “Company”) (NASDAQ: CBMG) recently completed a follow-on offering of 1,106,961 shares of its common stock, which includes the partial exercise of the over-allotment option of 77,549 shares, at a public offering price of $17.00 per share for total gross proceeds of approximately $18.8 million. CBMG intends to use the net proceeds received from this offering for preclinical studies, clinical trials, continued technology platform development, as well as for working capital and other general corporate purposes.
CBMG develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company’s GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and United States GMP standards. CBMG is headquartered in New York, New York.
CONTACT US TO LEARN MORE
- March 2019
- Cellular Biomedicines Group Inc.
- Target Geography
- North America